论文部分内容阅读
目的:评估丁苯酞联合美多巴治疗血管性帕金森综合征的临床疗效。方法:134例血管性帕金森患者随机分为血栓通组(n=42)、丁苯酞组(n=48)和美多巴组(n=44),分别给予复方血栓通胶囊和美多巴片、丁苯酞胶囊和美多巴片和美多巴片,疗程均为16周;并于治疗4、6、16周后观察临床疗效。结果:与美多巴组相比,各治疗组UPDRS评分均明显下降(P<0.05),临床疗效明显提高(P<0.01);丁苯酞组显效率及总有效率均明显优于血栓通组(P<0.05)。结论:丁苯酞联合美多巴治疗血管性帕金森综合征的效果满意,建议推广应用。
OBJECTIVE: To evaluate the clinical efficacy of butylphthalide combined with metoparamin in the treatment of vascular parkinsonism. Methods: A total of 134 patients with vascular parkinsonism were randomly divided into Xueshuantong group (n = 42), butylphthalide group (n = 48) and metopar group (n = 44) , Butylphthalide Capsules and Methylprednisolone tablets and Methomyl tablets, both for 16 weeks; and in the treatment of 4,6,16 weeks after the observation of clinical efficacy. Results: The UPDRS scores of all treatment groups were significantly decreased (P <0.05), and the clinical efficacy was significantly improved (P <0.01). The effective rate and total effective rate of butylphthalide group were significantly better than that of Xueshuantong Group (P <0.05). Conclusion: Butyphthalide combined with Madopar in the treatment of vascular parkinsonism is satisfactory, it is recommended to promote the application.